Flagstar Bank NA vs Zimmer Biomet Holdings Inc — how do they compare? Flagstar Bank NA trades at $11.38 (market cap $4.71B), while Zimmer Biomet Holdings Inc trades at $89.33 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3.6× Flagstar Bank NA's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 22 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| FLG | ZBH | |
|---|---|---|
Market Cap | $4.71B | $16.95B |
Volume | 7,410,589 | 2,505,240 |
Sector | Financials | Health |
52-Week High | $15.36 | $103.98 |
52-Week Low | $10.72 | $79.58 |
Typical Hold Time | 22 Days | 89 Days |
Enterprise Value | $15.25B | $24.02B |
Dividend Yield | 0.35% | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $11.44, up 1.24% with a bearish technical outlook despite recent earnings volatility. The company reported mixed quarterly results with Q2 2026 missing EPS estimates but maintains analyst optimism with a $17.07 consensus target. Fundamentals show improving profitability with net income turning positive in 2026, while valuation metrics present a mixed picture with high P/E but attractive P/B ratio of 0.62.
The stock offers potential upside from current depressed levels given the significant discount to book value and strong analyst buy ratings (60% consensus). Key risks include ongoing earnings volatility, competitive banking pressures, and the challenge of sustaining recent profitability improvements amid economic uncertainty.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Trailing returns across standard periods
Latest headlines on both assets
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →